Literature DB >> 23319743

Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production.

Hailan Liu1, Xi Wu, Zizheng Dong, Zhiyong Luo, Zhenwen Zhao, Yan Xu, Jian-Ting Zhang.   

Abstract

Fatty acid synthase (FASN) is a key enzyme in the synthesis of palmitate, the precursor of major nutritional, energetic, and signaling lipids. FASN expression is upregulated in many human cancers and appears to be important for cancer cell survival. Overexpression of FASN has also been found to associate with poor prognosis and higher risk of recurrence of human cancers. Indeed, elevated FASN expression has been shown to contribute to drug resistance. However, the mechanism of FASN-mediated drug resistance is currently unknown. In this study, we show that FASN overexpression causes resistance to multiple anticancer drugs via inhibiting drug-induced ceramide production, caspase 8 activation, and apoptosis. We also show that FASN overexpression suppresses tumor necrosis factor-α production and nuclear factor-κB activation as well as drug-induced activation of neutral sphingomyelinase. Thus, TNF-α may play an important role in mediating FASN function in drug resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319743      PMCID: PMC3617951          DOI: 10.1194/jlr.M033811

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  45 in total

1.  Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.

Authors:  Amith Panner; Courtney A Crane; Changjiang Weng; Alberto Feletti; Shanna Fang; Andrew T Parsa; Russell O Pieper
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

2.  Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.

Authors:  Baoguang Han; Han Xie; Qun Chen; Jian-Ting Zhang
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

Review 3.  Multiple control of interleukin-8 gene expression.

Authors:  Elke Hoffmann; Oliver Dittrich-Breiholz; Helmut Holtmann; Michael Kracht
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

4.  Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker.

Authors:  Hailan Liu; Jing-Yuan Liu; Xi Wu; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2010-07-18

Review 5.  Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses.

Authors:  Bill X Wu; Christopher J Clarke; Yusuf A Hannun
Journal:  Neuromolecular Med       Date:  2010-06-16       Impact factor: 3.843

6.  Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis.

Authors:  J P Jaffrézou; T Levade; A Bettaïeb; N Andrieu; C Bezombes; N Maestre; S Vermeersch; A Rousse; G Laurent
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

7.  Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4.

Authors:  Lynn M Knowles; Chen Yang; Andrei Osterman; Jeffrey W Smith
Journal:  J Biol Chem       Date:  2008-09-16       Impact factor: 5.157

8.  Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism.

Authors:  Norma Marchesini; Chiara Luberto; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

9.  Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients.

Authors:  P L Alo'; P Visca; A Marci; A Mangoni; C Botti; U Di Tondo
Journal:  Cancer       Date:  1996-02-01       Impact factor: 6.860

10.  Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas.

Authors:  P L Alò; P Visca; G Trombetta; A Mangoni; L Lenti; S Monaco; C Botti; D E Serpieri; U Di Tondo
Journal:  Tumori       Date:  1999 Jan-Feb
View more
  24 in total

1.  FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1.

Authors:  Xi Wu; Zizheng Dong; Chao J Wang; Lincoln James Barlow; Valerie Fako; Moises A Serrano; Yue Zou; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

Review 2.  Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.

Authors:  Satyendra C Tripathi; Johannes F Fahrmann; Jody V Vykoukal; Jennifer B Dennison; Samir M Hanash
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-23

3.  3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers.

Authors:  Dylan T Jones; Alessandro Valli; Syed Haider; Qifeng Zhang; Elizabeth A Smethurst; Zachary T Schug; Barrie Peck; Eric O Aboagye; Susan E Critchlow; Almut Schulze; Eyal Gottlieb; Michael J O Wakelam; Adrian L Harris
Journal:  Mol Cancer Ther       Date:  2018-11-26       Impact factor: 6.261

4.  Biochanin A inhibits lipopolysaccharide-induced inflammatory cytokines and mediators production in BV2 microglia.

Authors:  Yang Zhang; Wei-An Chen
Journal:  Neurochem Res       Date:  2014-11-29       Impact factor: 3.996

5.  De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer.

Authors:  Naser Jafari; James Drury; Andrew J Morris; Fredrick O Onono; Payton D Stevens; Tianyan Gao; Jinpeng Liu; Chi Wang; Eun Y Lee; Heidi L Weiss; B Mark Evers; Yekaterina Y Zaytseva
Journal:  Mol Cancer Res       Date:  2018-08-28       Impact factor: 5.852

6.  An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.

Authors:  Leslie E Lupien; Evan M Dunkley; Margaret J Maloy; Ian B Lehner; Maxwell G Foisey; Maddison E Ouellette; Lionel D Lewis; Darcy Bates Pooler; William B Kinlaw; Paul W Baures
Journal:  J Pharmacol Exp Ther       Date:  2019-07-12       Impact factor: 4.030

7.  Inhibition of FASN expression enhances radiosensitivity in human non-small cell lung cancer.

Authors:  Ning Zhan; Bin Li; Xiangying Xu; Jianyu Xu; Songliu Hu
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

8.  Inhibition of fatty acid synthase is protective in pulmonary hypertension.

Authors:  Neetu Singh; Amit Manhas; Gurpreet Kaur; Kumaravelu Jagavelu; Kashif Hanif
Journal:  Br J Pharmacol       Date:  2016-05-13       Impact factor: 8.739

Review 9.  Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing.

Authors:  Vinod S Bisht; Kuldeep Giri; Deepak Kumar; Kiran Ambatipudi
Journal:  Cancer Biol Ther       Date:  2021-10-25       Impact factor: 4.742

10.  Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.

Authors:  Chao J Wang; Deren Li; Jacob A Danielson; Evan H Zhang; Zizheng Dong; Kathy D Miller; Lang Li; Jian-Ting Zhang; Jing-Yuan Liu
Journal:  Cancer Lett       Date:  2021-04-01       Impact factor: 9.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.